Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erding – page 105

1 344 clinical trials in Erding, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erding at a glance
1 344
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 344 trials in Erding

Open in trial search

Study on the Effects of EDG-5506 for Adults and Adolescents with Becker Muscular Dystrophy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:EDG-5506
  • Sponsor:Edgewise Therapeutics Inc.

Study on Botensilimab and Balstilimab for Patients with Advanced Melanoma Resistant to Previous Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Balstilimab
  • Sponsor:Agenus Inc.

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Low-Risk Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Hepatitis D

Not recruiting

Study on Bulevirtide Treatment for Patients with Chronic Hepatitis D

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Gilead Sciences Inc.

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Study of Telisotuzumab Vedotin for Adults with Advanced Non-Squamous Non-Small Cell Lung Cancer

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Telisotuzumab Vedotin
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Not recruiting

Study of Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of LY3473329 for Adults with High Lipoprotein(a) Levels at Risk for Heart Problems

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Muvalaplin
  • Sponsor:Eli Lilly & Co.

Study Comparing Olaparib and Pembrolizumab with Chemotherapy and Pembrolizumab for Patients with Advanced Triple-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab and Chemotherapy for Patients with Triple Negative Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erding

What the registry says about research in the country

01 Hematologic Disorders

Innovative research focusing on Myelodysplastic Syndrome (MDS), comparing novel therapeutic approaches for patients with lower-risk conditions. The studies aim to evaluate treatment effectiveness in managing blood cell production disorders.

  • Lower-risk MDS management
  • Blood cell production therapy
  • Treatment conversion studies

Current trials are investigating comparative effectiveness of different therapeutic agents in managing transfusion dependency.

02 Blood Disorders

Advanced research into polycythemia vera treatment resistance, utilizing artificial intelligence to predict treatment outcomes. Studies focus on understanding hydroxyurea resistance patterns in affected patients.

  • Treatment resistance evaluation
  • AI-driven predictions
  • Therapeutic monitoring

Research combines traditional clinical approaches with modern machine learning techniques to optimize treatment strategies.

03 Cardiovascular Medicine

Groundbreaking research on acute coronary syndrome and atrial fibrillation, exploring optimized antiplatelet therapy protocols. Studies evaluate new approaches for patients undergoing percutaneous coronary intervention.

  • Antiplatelet therapy optimization
  • Cardiac intervention outcomes
  • Bleeding risk management

Investigations focus on balancing therapeutic efficacy with safety in complex cardiac conditions.

04 Advanced Myelofibrosis

Clinical investigations of intermediate and high-risk myelofibrosis, exploring combination therapies and novel treatment approaches. Research aims to establish optimal dosing strategies for enhanced patient outcomes.

  • Combination therapy assessment
  • Treatment tolerability studies
  • Dose optimization research

Studies focus on developing safer and more effective treatment protocols for advanced stages of the disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.